MedTrace Logo

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 572

Last updated 2026-05-20

No results posted yet for this study

Summary

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Conditions

  • Graft-versus-host Disease (GVHD)

Interventions

DRUG

Tacrolimus (Tac)

Tablet or intravenously (IV)

DRUG

Methotrexate (MTX)

Intravenously (IV)

DRUG

Ruxolitinib (Rux)

Tablet

DRUG

Cyclophosphamide

Intravenously (IV)

DRUG

Mycophenolate mofetil (MMF)

Tablet or intravenously (IV)

Sponsors & Collaborators

  • Blood and Marrow Transplant Clinical Trials Network

    collaborator NETWORK

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Incyte Corporation

    lead INDUSTRY

Principal Investigators

  • Incyte Medical Monitor · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-02
Primary Completion
2031-01-17
Completion
2031-01-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06615050 on ClinicalTrials.gov